The Ultraspect xpress.cardiac nuclear imaging solution reduced SPECT radiation dose.

January 3, 2014 — As the global medical isotope shortage continues indefinitely following the plant leak in South Africa, Berks Cardiologists Ltd., a cardiovascular imaging center in central Pennsylvania, is continuing to operate at the same procedure volume and with their lower-dose cardiac nuclear medicine imaging protocols. The facility relies on software from UltraSPECT, a provider of image reconstruction technology that reduces radiopharmaceutical dose and acquisition time for nuclear medicine (NM) exams.
 
Berks Cardiologists is a private practice in Wyomissing, Penn. with a staff that includes 14 cardiologists and performs about 100 SPECT exams a week. The practice was initially looking for software to improve their image quality and found a solution that only provides them with high-resolution images and the ability to use half the injected dose of the nuclear imaging agent Technetium-99m (Tc-99m).
 
"Wide Beam Reconstruction technology from UltraSPECT has been instrumental in our ability to maintain our high patient throughput throughout this technetium shortage,” said James Reibsane, CNMT, director of diagnostic and technical services, Berks. “With our protocol of low-dose imaging, our business operations continue, and our patients are all imaged as planned and as needed. Few cardiovascular imaging facilities across the country can say the same.”
 
Shortages of Tc-99m can have significant impact on healthcare facilities’ operations and, more significantly, on the care of their patients. Without a solution like the low dose software from UltraSPECT, implications can include:
-Inability to provide patients with the necessary nuclear medicine tests
-Delays and rescheduling of exams for patients
-The need to send high-risk patients for interventional procedures without the most necessary test results
-Loss of revenue to a practice 
 
“Since the heavy shortage in 2009, it is known that nuclear isotope shortages are guaranteed to happen and are nearly always unexpected,” said Yossi Srour, president and CEO, UltraSPECT. “Low dose protocols are needed now more than ever with the increase in these shortages combined with the ongoing implementation of low dose ASNC guidelines.”
 
UltraSPECT’s Xpress3.Cardiac solution uses the company’s exclusive WBR (wide-beam reconstruction) technology to deliver half-dose cardiac imaging with high image quality and undiminished diagnostic certainty. It minimizes the radiation dose to both the patients and the staff administering the exams.
 
 
Read the 2017 article "FDA Clears Path for First Domestic Supply of Tc-99m Isotope." 
 
For more information: www.ultraspect.com

Related Content

Feature | Nuclear Imaging

The "Nuclear Medicine Market Size, Share & Trends Analysis Report by Product (Diagnostics (SPECT, PET)), Therapeutics ...

Time May 26, 2022
arrow
News | Proton Therapy

May 25, 2022 — B dot Medical Inc. and Research Center for Nuclear Physics, Osaka University (RCNP) have conducted a ...

Time May 25, 2022
arrow
News | Contrast Media

May 19 2022 — Recent disruptions in a pharmaceutical supply chain have impacted the global availability of GE Healthcare ...

Time May 19, 2022
arrow
News | Contrast Media

May 18, 2022 —According to ARRS’ American Journal of Roentgenology (AJR), to ensure that patients with emergent or life ...

Time May 18, 2022
arrow
News | Radiopharmaceuticals and Tracers

May 16, 2022 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization ...

Time May 16, 2022
arrow
News | Contrast Media

May 13, 2022 — The ACR Committee on Drugs and Contrast Media, within the ACR Commission on Quality and Safety, is aware ...

Time May 13, 2022
arrow
News | Nuclear Imaging

May 9, 2022 — Novartis announced a temporary, voluntary suspension of production at its radioligand therapy production ...

Time May 09, 2022
arrow
News | Proton Therapy

May 5, 2022 — IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology and the ...

Time May 05, 2022
arrow
News | Coronavirus (COVID-19)

May 4, 2022 — While the COVID-19 pandemic transitions through various phases, nuclear cardiology teams should maintain a ...

Time May 04, 2022
arrow
News | Quality Assurance (QA)

May 3, 2022 — Sun Nuclear Corporation, a wholly-owned subsidiary of Mirion Technologies, Inc., today announced the ...

Time May 03, 2022
arrow
Subscribe Now